Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty
pharmaceutical company focused on developing and commercializing
products for the treatment of central nervous system (CNS)
diseases, today reported financial results for first quarter 2016
and associated company developments.
Commercial Update
First quarter 2016 product prescriptions for Trokendi XR® and
Oxtellar XR®, as reported by IMS, totaled 114,773, a 49.7% increase
over the first quarter of 2015.
|
|
|
|
|
|
|
|
|
Prescriptions |
|
|
|
|
Q1 2016 |
|
Q1 2015 |
|
Change % |
|
|
|
|
|
|
|
Trokendi XR |
|
85,987 |
|
55,227 |
|
|
55.7 |
% |
Oxtellar XR |
|
28,786 |
|
21,463 |
|
|
34.1 |
% |
|
|
|
|
|
|
|
Total |
|
114,773 |
|
76,690 |
|
|
49.7 |
% |
|
|
|
|
|
|
|
|
|
Source Data: Product prescriptions as reported by
IMS |
|
|
|
|
|
|
|
|
|
Total revenue for the first quarter of 2016 was $43.1 million, a
53.1% increase over $28.1 million in the same period last year.
Total revenue for both periods consisted almost exclusively of net
product sales.
|
|
|
|
|
|
|
|
|
Net Product Sales ($mil.) |
|
|
|
|
Q1 2016 |
|
Q1 2015 |
|
Change % |
|
|
|
|
|
|
|
Trokendi XR |
|
$ |
32.3 |
|
|
$ |
20.9 |
|
|
|
54.5 |
% |
Oxtellar XR |
|
$ |
10.7 |
|
|
$ |
7.2 |
|
|
|
49.3 |
% |
|
|
|
|
|
|
|
Total |
|
$ |
43.0 |
|
|
$ |
28.1 |
|
|
|
53.1 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
Consistent with industry trends and the Company’s experience in
the first quarter last year, product prescriptions and net product
sales for Trokendi XR and Oxtellar XR were unfavorably impacted by
the reset of insurance coverage at the beginning of the year, with
high deductible and high co-pay programs. Additionally, changes in
wholesaler inventory levels and ordering patterns during the first
quarter of 2016 had the effect of reducing net product sales by
approximately $3 million in the first quarter of 2016.
“Our business continues to post strong growth compared to last
year. Total first quarter IMS prescriptions, and net product sales
grew by 50% or more compared to the same period last year. We
continue to build on the momentum we finished with last year
promoting the benefits of our products to patients with epilepsy,”
said Jack Khattar, President and CEO of Supernus
Pharmaceuticals.
Regarding our supplemental new drug application requesting
approval to expand the Trokendi XR label to include treatment of
migraine in adults, we are ready to launch the new migraine
indication once we receive full approval from the FDA.
Progress of Product Pipeline
Enrollment continues for both Phase III trials for SPN-810,
which is currently in development for Impulsive Aggression in
patients who have ADHD, and for the Phase IIb trial for SPN-812,
currently in development for ADHD. The Company continues to expect
Phase III data for SPN-810 to be available by mid 2017, and data
from the SPN-812 Phase IIb trial to be available by early 2017.
“In addition to our recent findings on the favorable emerging
clinical profile of SPN-812 as it relates to adverse events, we
completed the evaluation of the cardiac effects portion of the
single ascending and multiple ascending dose study. We are pleased
to report that there was no clinically significant change in QT
interval and other ECG parameters. We believe these
additional safety data in adult healthy volunteers, which show a
lack of cardiac effects, are very encouraging and further
strengthen the differentiation of SPN-812,” said Jack
Khattar.
Collaboration Update
Shire recently announced positive results of SHP465 in a safety
and efficacy study in children and adolescents with ADHD. The study
addresses a key U.S. Food and Drug Administration (FDA)
requirement, keeping SHP465 on track for resubmission in the fourth
quarter of 2016 and a potential launch in the second half of 2017,
if it is approved by the FDA. SHP465 was originally developed by
Shire Laboratories, the former division of Shire that subsequently
became Supernus Pharmaceuticals. Based on the agreement between
Supernus and Shire, Shire will pay to Supernus a single-digit
percentage royalty on net sales of the product.
Operating Expenses
Research and development expenses in the first quarter of 2016
were $10.6 million, as compared to $3.7 million in the same quarter
the prior year. This increase is primarily due to the ongoing Phase
III testing of SPN-810 and Phase IIb testing of SPN-812.
Selling, general and administrative expenses in the first
quarter of 2016 were $25.2 million, as compared to $19.4 million in
the same quarter the prior year. The increase is primarily due to
the continued increase in our sales and marketing efforts for both
Trokendi XR and Oxtellar XR and the efforts in preparing for the
launch of the migraine indication for Trokendi XR.
Operating Income and Earnings Per Share
Operating income in the first quarter of 2016 was $5.3 million,
an increase of 55.0% over operating income of $3.4 million in the
same period last year. This improvement in operating income is
primarily due to the increase in net product sales.
Diluted earnings per share were $0.08 in the first quarter ended
March 31, 2016, compared to $0.02 in the same period last
year.
Weighted-average diluted common shares outstanding were
approximately 51.2 million in the first quarter of 2016, as
compared to approximately 44.9 million in the same period the prior
year.
Capital Resources
As of March 31, 2016, the Company had $114.0 million in cash,
cash equivalents, marketable securities, and long term marketable
securities, as compared to $117.2 million at December 31, 2015.
As of March 31, 2016, approximately $6.6 million of the
Company’s six year, $90 million notes, bearing interest at 7.5% per
annum, remain outstanding.
Financial Guidance
For full year 2016, the Company reiterates its expectation that
net product sales will range from $200 million to $210 million,
R&D expenses to range from $55 million to $65 million, and
operating income to range from $28 million to $35 million.
Conference Call Details
The Company will hold a conference call hosted by Jack Khattar,
President and Chief Executive Officer, and Greg Patrick, Vice
President and Chief Financial Officer, to discuss these results at
9:00 a.m. ET, on Wednesday, May 4, 2016. An accompanying webcast
also will be provided.
Please refer to the information below for conference call
dial-in information and webcast registration. Callers should dial
in approximately 10 minutes prior to the start of the call.
|
|
Conference dial-in: |
(877) 288-1043 |
International dial-in: |
(970) 315-0267 |
Conference ID: |
94042155 |
Conference Call Name: |
Supernus Pharmaceuticals 1Q 2016
Earnings Conference Call |
Following the live call, a replay
will be available on the Company's website, www.supernus.com, under
‘Investors’. |
|
|
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical
company focused on developing and commercializing products for the
treatment of central nervous system diseases. The Company has two
marketed products for epilepsy, Oxtellar XR® (extended-release
oxcarbazepine) and Trokendi XR® (extended-release topiramate). The
Company is also developing several product candidates to address
large market opportunities in psychiatry, including SPN-810 for the
treatment of Impulsive Aggression in ADHD patients and SPN-812 for
the treatment of ADHD.
Forward-Looking Statements:
This press release includes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. These statements do not convey historical information, but
relate to predicted or potential future events that are based upon
management's current expectations. These statements are subject to
risks and uncertainties that could cause actual results to differ
materially from those expressed or implied by such statements. In
addition to the factors mentioned in this press release, such risks
and uncertainties include, but are not limited to, the Company’s
ability to sustain and increase its profitability; the Company’s
ability to raise sufficient capital to fully implement its
corporate strategy; the implementation of the Company’s corporate
strategy; the Company’s future financial performance and projected
expenditures; the Company’s ability to increase the number of
prescriptions written for each of its products; the Company’s
ability to increase its net revenue; the Company’s ability to enter
into future collaborations with pharmaceutical companies and
academic institutions or to obtain funding from government
agencies; the Company’s product research and development
activities, including the timing and progress of the Company’s
clinical trials, and projected expenditures; the Company’s ability
to receive, and the timing of any receipt of, regulatory approvals
to develop and commercialize the Company’s product candidates; the
Company’s ability to protect its intellectual property and operate
its business without infringing upon the intellectual property
rights of others; the Company’s expectations regarding federal,
state and foreign regulatory requirements; the therapeutic
benefits, effectiveness and safety of the Company’s product
candidates; the accuracy of the Company’s estimates of the size and
characteristics of the markets that may be addressed by its product
candidates; the Company’s ability to increase its manufacturing
capabilities for its products and product candidates; the Company’s
projected markets and growth in markets; the Company’s product
formulations and patient needs and potential funding sources; the
Company’s staffing needs; and other risk factors set forth from
time to time in the Company’s SEC filings made pursuant to Section
13 or 15(d) of the Securities Exchange Act of 1934, as amended. The
Company undertakes no obligation to update the information in this
press release to reflect events or circumstances after the date
hereof or to reflect the occurrence of anticipated or unanticipated
events.
|
Supernus Pharmaceuticals, Inc. |
Condensed Consolidated Balance
Sheets |
(in thousands) |
|
|
|
|
|
|
|
|
|
|
March 31, 2016 |
|
|
December 31, 2015 |
|
|
|
(unaudited) |
|
|
|
|
|
|
|
|
|
|
Cash, cash equivalents
and marketable securities |
|
$ |
45,257 |
|
$ |
62,190 |
Accounts receivable,
net |
|
|
30,651 |
|
|
25,908 |
Inventories, net |
|
|
13,044 |
|
|
12,587 |
Prepaid expenses and
other current assets |
|
|
5,003 |
|
|
5,261 |
Total Current
Assets |
|
|
93,955 |
|
|
105,946 |
|
|
|
|
|
|
|
Long
term marketable securities |
|
|
68,790 |
|
|
55,009 |
Property and equipment,
net |
|
|
3,866 |
|
|
3,874 |
Deferred legal
fees |
|
|
11,444 |
|
|
22,503 |
Intangible assets,
net |
|
|
16,108 |
|
|
976 |
Other non-current
assets |
|
|
311 |
|
|
318 |
Total Assets |
|
$ |
194,474 |
|
$ |
188,626 |
|
|
|
|
|
|
|
Accounts payable |
|
$ |
2,646 |
|
$ |
4,314 |
Accrued sales
deduction |
|
|
28,697 |
|
|
26,794 |
Accrued expenses |
|
|
22,573 |
|
|
24,813 |
Deferred licensing
revenue |
|
|
208 |
|
|
176 |
Total Current
Liabilities |
|
|
54,124 |
|
|
56,097 |
|
|
|
|
|
|
|
Deferred licensing
revenue, net of current portion |
|
|
1,658 |
|
|
1,390 |
Convertible notes, net
of discount |
|
|
5,627 |
|
|
7,085 |
Other non-current
liabilities |
|
|
4,391 |
|
|
4,325 |
Derivative
liabilities |
|
|
535 |
|
|
854 |
Total Liabilities |
|
|
66,335 |
|
|
69,751 |
|
|
|
|
|
|
|
Total Stockholders'
Equity |
|
|
128,139 |
|
|
118,875 |
Total Liabilities &
Stockholders' Equity |
|
$ |
194,474 |
|
$ |
188,626 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Supernus Pharmaceuticals, Inc. |
Consolidated Statements of
Operations |
(in thousands, except share and per share
data) |
|
|
|
|
|
|
|
Three Months ended March 31, |
|
2016 |
|
2015 |
|
|
|
|
|
|
|
(unaudited) |
Revenue |
|
|
|
|
|
Net product sales |
$ |
|
43,025 |
|
|
$ |
|
28,097 |
|
Licensing revenue |
|
|
50 |
|
|
|
|
36 |
|
|
|
|
|
|
|
Total
revenue |
|
|
43,075 |
|
|
|
|
28,133 |
|
|
|
|
|
|
|
Costs and expenses |
|
|
|
|
|
Cost of product sales |
|
|
2,035 |
|
|
|
|
1,618 |
|
Research and development |
|
|
10,562 |
|
|
|
|
3,683 |
|
Selling, general and
administrative |
|
|
25,160 |
|
|
|
|
19,402 |
|
|
|
|
|
|
|
Total costs and
expenses |
|
|
37,757 |
|
|
|
|
24,703 |
|
|
|
|
|
|
|
Operating income |
|
|
5,318 |
|
|
|
|
3,430 |
|
|
|
|
|
|
|
Other income
(expense) |
|
|
|
|
|
Interest income |
|
|
331 |
|
|
|
|
113 |
|
Interest expense |
|
|
(179 |
) |
|
|
|
(381 |
) |
Changes in fair value of derivative
liabilities |
|
|
101 |
|
|
|
|
(49 |
) |
Loss on extinguishment of debt |
|
|
(382 |
) |
|
|
|
(2,134 |
) |
Other income |
|
|
(4 |
) |
|
|
|
- |
|
|
|
|
|
|
|
Total other
expense |
|
|
(133 |
) |
|
|
|
(2,451 |
) |
|
|
|
|
|
|
Earnings before income
taxes |
|
|
5,185 |
|
|
|
|
979 |
|
|
|
|
|
|
|
Income tax expense |
|
|
198 |
|
|
|
|
62 |
|
|
|
|
|
|
|
Net income |
$ |
|
4,987 |
|
|
$ |
|
917 |
|
|
|
|
|
|
|
Income per common
share: |
|
|
|
|
|
Basic |
$ |
|
0.10 |
|
|
$ |
|
0.02 |
|
Diluted |
$ |
|
0.08 |
|
|
$ |
|
0.02 |
|
|
|
|
|
|
|
Weighted-average number
of common shares: |
|
|
|
|
|
Basic |
|
|
49,240,099 |
|
|
|
|
44,563,299 |
|
Diluted |
|
|
51,152,072 |
|
|
|
|
44,901,298 |
|
|
|
|
|
|
|
CONTACTS:
Jack A. Khattar, President and CEO
Gregory S. Patrick, Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591
or
INVESTOR CONTACT:
Peter Vozzo
Westwicke Partners
Office: (443) 213-0505
Mobile: (443) 377-4767
Email: peter.vozzo@westwicke.com
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Apr 2023 to Apr 2024